DICOT Stock Overview
Engages in the development of pharmaceutical products in Sweden.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Dicot Pharma AB Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.23 |
52 Week High | SEK 0.58 |
52 Week Low | SEK 0.096 |
Beta | 1.47 |
11 Month Change | 27.21% |
3 Month Change | -24.84% |
1 Year Change | 109.09% |
33 Year Change | -68.10% |
5 Year Change | -91.22% |
Change since IPO | -97.33% |
Recent News & Updates
Shareholder Returns
DICOT | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 6.5% | 3.2% | 1.6% |
1Y | 109.1% | 32.3% | 21.2% |
Return vs Industry: DICOT exceeded the Swedish Pharmaceuticals industry which returned 37.3% over the past year.
Return vs Market: DICOT exceeded the Swedish Market which returned 20.9% over the past year.
Price Volatility
DICOT volatility | |
---|---|
DICOT Average Weekly Movement | 14.8% |
Pharmaceuticals Industry Average Movement | 11.0% |
Market Average Movement | 5.4% |
10% most volatile stocks in SE Market | 11.0% |
10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: DICOT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: DICOT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 3 | Elin Trampe | www.dicotpharma.com |
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It is developing LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024.
Dicot Pharma AB Fundamentals Summary
DICOT fundamental statistics | |
---|---|
Market cap | SEK 409.12m |
Earnings (TTM) | -SEK 52.66m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.8x
P/E RatioIs DICOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DICOT income statement (TTM) | |
---|---|
Revenue | SEK 0 |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 0 |
Other Expenses | SEK 52.66m |
Earnings | -SEK 52.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.03 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did DICOT perform over the long term?
See historical performance and comparison